fbpx
QQQ
+ 1.73
340.90
+ 0.5%
DIA
+ 5.77
327.19
+ 1.73%
SPY
+ 5.82
409.10
+ 1.4%
TLT
-2.44
148.17
-1.67%
GLD
+ 2.00
162.93
+ 1.21%

4 Reasons You Can Expect Allscripts To Outperform

by
September 11, 2017 10:49 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Analysts at Cowen highlighted four reasons why investors should consider buying Allscripts Healthcare Solutions Inc (NASDAQ:MDRX). The firm's Charles Rhyee upgraded Allscripts' stock rating from Market Perform to Outperform with a price target raised from $13 to $16.

1. Improving Fundamentals

Allscripts has developed a reputation over the past few quarters of reporting consistent results that at least matched expectations if not came in higher than expected, Rhyee commented in his upgrade note. This has resulted in a reduction in volatility earnings as the company shifted its business more towards a recurring revenue model.

tipranks.png

2. EIS Acquisition

Allscripts' acquisition of McKesson Corporation (NYSE:MCK)'s Enterprise Information Solutions Business will prove to be complementary to its current offerings and add incremental revenue along with cost synergies to fuel growth.

3. Free Cash Flow

The healthcare company boasts a "strong" 9.3-percent free cash flow yield which is superior to the group average of 4.4 percent, the analyst also noted. This could result in incremental earnings from a share buyback program, debt repayment or further M&A deals. In fact, one year's worth of free cash flow alone could be up to 10 percent accretive to the company's adjusted EPS.

4. Attractive Multiple

Finally, the analyst's $16 price target implies the stock will trade at 20.9x on expected 2018 EPS of $0.76 as opposed to the current multiple of 16.3x and the group's average multiple of 27.5x.

At last check, shares of Allscripts were up 5.21 percent at $13.73.

Related Links:

7 Biggest Price Target Changes For Monday

Benzinga's Top Upgrades, Downgrades For September 11, 2017

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Cowen Downgrades Cardinal Health, McKesson Amid Limited Near-Term Growth Drivers

10 Stocks That Earned Short Sellers The Most Profits In 2020

The coronavirus outbreak severely disrupted the stock market and the economy in 2020. While many stocks ultimately recovered their early-year losses thanks to aggressive federal stimulus spending, some stocks are still feeling the pandemic pain. read more

Morgan Stanley Says 'Revisiting' COVID-19 Vaccine Distribution Opportunity For McKesson; Notes Co. Is Distributor For Moderna Vaccine Doses Through June 2021 And Says Expects 'the benefit to be greater to fiscal 2022 than we initially expected.'

Baird: What Rite Aid's Renewed Deal With Distributor McKesson Means For Both Companies